Gene Mack

Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer

Retrieved on: 
Monday, April 8, 2024
MSD, Employment, Fordham University, Biotechnology, CFO, Patient, Research, Merck, Gruntal & Co., Acquisition, IPO, MBA, Initial, Therapy, HSBC, Gene Mack, Pharmaceutical industry

BETHESDA, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces the appointment of Gene Mack, MBA as its chief financial officer, effective as of April 8, 2024.

Key Points: 
  • BETHESDA, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces the appointment of Gene Mack, MBA as its chief financial officer, effective as of April 8, 2024.
  • “We are thrilled to welcome Gene as our new CFO,” commented Gain CEO Matthias Alder.
  • Prior to joining Gain, Gene was CFO at privately held Imcyse SA between 2021 and 2023.
  • “I am excited to join Gain Therapeutics during this important stage of corporate growth and scientific progression.

DGAP-News: Imcyse Appoints Gene Mack, MBA as Chief Financial Officer

Retrieved on: 
Wednesday, November 3, 2021
MSD, CFO, Biotechnology, IPO, Lazard, Peptide, Catholic University of Leuven (1834–1968), Disease, MBA, HSBC, Patient, Gruntal & Co., Degenerative disease, Catholic higher education, Company, Clinical trial, Acquisition, Cell death, CD4, Gene Mack, Fordham University, Security (finance), Pharmaceutical industry, Vaccine

Lige, Belgium, November 3, 2021 - Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases, today announced the appointment of Gene Mack, MBA, as Chief Financial Officer.

Key Points: 
  • Lige, Belgium, November 3, 2021 - Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases, today announced the appointment of Gene Mack, MBA, as Chief Financial Officer.
  • "We are thrilled to welcome Gene as our new CFO," said Denis Bedoret, Ph.D., Chief Executive Officer of Imcyse.
  • Mr. Mack joins Imcyse from OncoC4, a privately held biotechnology company that spun out of MSD's acquisition of OncoImmune.
  • Beyond type 1 diabetes, Imcyse is developing a pipeline of Imotopes(TM) for the treatment of several autoimmune diseases.

Imcyse Appoints Gene Mack, MBA as Chief Financial Officer

Retrieved on: 
Wednesday, November 3, 2021
Child development stages, CFO, Biotechnology, Peptide, IPO, Lazard, Catholic University of Leuven (1834–1968), Disease, MBA, HSBC, Patient, Gruntal & Co., Degenerative disease, Catholic higher education, Company, Clinical trial, Acquisition, Cell death, CD4, GLOBE, Gene Mack, Fordham University, Vaccine

LIGE, Belgium, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases, today announced the appointment of Gene Mack, MBA, as Chief Financial Officer.

Key Points: 
  • LIGE, Belgium, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases, today announced the appointment of Gene Mack, MBA, as Chief Financial Officer.
  • We are thrilled to welcome Gene as our new CFO, said Denis Bedoret, Ph.D., Chief Executive Officer of Imcyse.
  • Mr. Mack joins Imcyse from OncoC4, a privately held biotechnology company that spun out of MSDs acquisition of OncoImmune.
  • In addition to orchestrating the successful transaction between the two companies, he oversaw OncoC4s financial establishment.

Coya Therapeutics Appoints Gene Mack as Chief Financial Officer

Retrieved on: 
Tuesday, October 12, 2021
Columbia University College of Dental Medicine, HSBC, Columbia University Vagelos College of Physicians and Surgeons, Cryopreservation, Degenerative disease, Therapy, Surgeon, Cerebrovascular disease, Gruntal & Co., Negotiation, Weill Cornell Medicine, Exosome, Merck, Wall Street, GLOBE, MBA, Frontotemporal dementia, Growth, CFO, Industry, Aneurysm, ALS, Pectus carinatum, Gene Mack, Coya, Stroke, Lazard Capital Markets, Physician, BS, Acquisition, Disease, Patient, Fordham University, Research, TM, Pharmaceutical industry

HOUSTON, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc. (Coya), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Treg) and Treg-derived exosome therapeutics for neurodegenerative and autoimmune diseases, today announced the appointment of Gene Mack as Chief Financial Officer effective immediately.

Key Points: 
  • HOUSTON, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc. (Coya), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Treg) and Treg-derived exosome therapeutics for neurodegenerative and autoimmune diseases, today announced the appointment of Gene Mack as Chief Financial Officer effective immediately.
  • We are pleased to welcome Gene, an esteemed biotech executive, at such an exciting time for Coya, said Howard Berman, Ph.D., Chief Executive Officer of Coya Therapeutics.
  • Gene has deep financial and business development expertise, as well as a strong track record for enhancing operational capabilities to drive growth.
  • Prior to joining Coya Therapeutics in 2021, Mr. Mack was Chief Financial Officer of OncoC4 overseeing the spin-out and negotiation of Merck MSDs acquisition of OncoImmune.